- Home
- ACRS vs SPCE Comparison
ACRS vs SPCE Comparison
Compare ACRS & SPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- SPCE
- Stock Information
- Founded
- ACRS 2012
- SPCE 2017
- Country
- ACRS United States
- SPCE United States
- Employees
- ACRS N/A
- SPCE N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- SPCE Transportation Services
- Sector
- ACRS Health Care
- SPCE Consumer Discretionary
- Exchange
- ACRS Nasdaq
- SPCE Nasdaq
- Market Cap
- ACRS 198.2M
- SPCE 226.9M
- IPO Year
- ACRS 2015
- SPCE N/A
- Fundamental
- Price
- ACRS $2.31
- SPCE $3.92
- Analyst Decision
- ACRS Strong Buy
- SPCE Hold
- Analyst Count
- ACRS 9
- SPCE 5
- Target Price
- ACRS $9.25
- SPCE $10.60
- AVG Volume (30 Days)
- ACRS 1.3M
- SPCE 5.5M
- Earning Date
- ACRS 11-06-2025
- SPCE 11-13-2025
- Dividend Yield
- ACRS N/A
- SPCE N/A
- EPS Growth
- ACRS N/A
- SPCE N/A
- EPS
- ACRS N/A
- SPCE N/A
- Revenue
- ACRS $16,789,000.00
- SPCE $1,698,000.00
- Revenue This Year
- ACRS N/A
- SPCE N/A
- Revenue Next Year
- ACRS N/A
- SPCE $2,908.26
- P/E Ratio
- ACRS N/A
- SPCE N/A
- Revenue Growth
- ACRS N/A
- SPCE N/A
- 52 Week Low
- ACRS $1.05
- SPCE $2.18
- 52 Week High
- ACRS $5.17
- SPCE $8.19
- Technical
- Relative Strength Index (RSI)
- ACRS 62.06
- SPCE 49.20
- Support Level
- ACRS $2.24
- SPCE $3.54
- Resistance Level
- ACRS $2.47
- SPCE $4.17
- Average True Range (ATR)
- ACRS 0.19
- SPCE 0.36
- MACD
- ACRS 0.03
- SPCE -0.05
- Stochastic Oscillator
- ACRS 77.92
- SPCE 22.49
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.